Health-related quality of life and disease symptoms in postmenopausal women with HR(+), HER2(-) advanced breast cancer treated with everolimus plus exemestane versus exemestane monotherapy
Campone, Mario × Beck, J Thaddeus Gnant, Michael Neven, Patrick Pritchard, Kathleen I Bachelot, Thomas Provencher, Louise Rugo, Hope S Piccart, Martine Hortobagyi, Gabriel N Nunzi, Martina Heng, Daniel Y C Baselga, José Komorowski, Anna Noguchi, Shinzaburo Horiguchi, Jun Bennett, Lee Ziemiecki, Ryan Zhang, Jie Cahana, Ayelet Taran, Tetiana Sahmoud, Tarek Burris, Howard A #
Clayton-Wray Publications Ltd.
Current Medical Research and Opinion vol:29 issue:11 pages:1463-73
Everolimus (EVE)+exemestane (EXE; n = 485) more than doubled median progression-free survival versus placebo (PBO) + EXE (n = 239), with a manageable safety profile and no deterioration in health-related quality-of-life (HRQOL) in patients with hormone-receptor-positive (HR(+)) advanced breast cancer (ABC) who recurred or progressed on/after nonsteroidal aromatase inhibitor (NSAI) therapy. To further evaluate EVE + EXE impact on disease burden, we conducted additional post-hoc analyses of patient-reported HRQOL.